|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/21 | |
| A61P 27/00 |
| (11) | Patento numeris | 2916859 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13792162.3 |
| Europos patento paraiškos padavimo data | 2013-11-01 | |
| (97) | Europos patento paraiškos paskelbimo data | 2015-09-16 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-06-28 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2013/068056 |
| Data | 2013-11-01 |
| (87) | Numeris | WO 2014/071183 |
| Data | 2014-05-08 |
| (30) | Numeris | Data | Šalis |
| 201261721810 P | 2012-11-02 | US |
| (72) |
MILLER, Sheldon S., US
MAMINISHKIS, Arvydas, US
REMÉ, Charlotte E., CH
|
| (73) |
Merck Patent GmbH,
Frankfurter Strasse 250, 64293 Darmstadt,
DE
The U.S.A. as represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, MD 20892-7660, US |
| (54) | METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDERGOING TREATMENT WITH A MEK INHIBITOR |
| METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDERGOING TREATMENT WITH A MEK INHIBITOR |